An Observational Post-Marketing Safety Registry of Sativex®

• Status: Completed
• Trial end date: 2015-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this registry is to monitor safety outcomes of patients who are receiving Sativex® for Multiple Sclerosis (MS) spasticity and for off-label indications in the United Kingdom (UK), Germany and Sweden.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: GW Pharmaceuticals Ltd.
• Treatments: Dronabinol; Nabiximols

Criteria

Inclusion Criteria:

• All patients who are prescribed Sativex® in the UK

• Patients who are prescribed Sativex® from selected specialist neurology centres in Germany and Sweden.